{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:31:12Z","timestamp":1790188272279,"version":"4.1.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.tcm.2023.01.008","type":"journal-article","created":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T01:19:51Z","timestamp":1675559991000},"page":"215-222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases"],"prefix":"10.1016","volume":"34","author":[{"given":"Fei","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avash","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet A.","family":"Khetarpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenfei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A","family":"Zelniker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Rosenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Qamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.tcm.2023.01.008_bib0001","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.tcm.2023.01.008_bib0002","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1016\/j.jacc.2020.09.610","article-title":"VLDL cholesterol accounts for one-half of the risk of myocardial infarction associated with apoB-containing lipoproteins","volume":"76","author":"Balling","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.tcm.2023.01.008_bib0003","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1016\/j.jacc.2020.10.008","article-title":"Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease","volume":"76","author":"Castaner","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.tcm.2023.01.008_bib0004","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.tcm.2023.01.008_bib0005","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","article-title":"The evolving future of PCSK9 inhibitors","volume":"72","author":"Rosenson","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.tcm.2023.01.008_bib0006","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia","volume":"363","author":"Musunuru","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.tcm.2023.01.008_bib0007","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrendo.2017.119","article-title":"Angiopoietin-like 3 in lipoprotein metabolism","volume":"13","author":"Kersten","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.tcm.2023.01.008_bib0008","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1194\/jlr.M200367-JLR200","article-title":"Regulation of the angiopoietin-like protein 3 gene by LXR","volume":"44","author":"Kaplan","year":"2003","journal-title":"J Lipid Res"},{"issue":"7","key":"10.1016\/j.tcm.2023.01.008_bib0009","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1194\/jlr.M500005-JLR200","article-title":"Differential regulation and properties of angiopoietin-like proteins 3 and 4","volume":"46","author":"Ge","year":"2005","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.tcm.2023.01.008_bib0010","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cmet.2016.07.012","article-title":"Loss of function of GALNT2 lowers high-density lipoproteins in humans, nonhuman primates, and rodents","volume":"24","author":"Khetarpal","year":"2016","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.tcm.2023.01.008_bib0011","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/ng814","article-title":"Angptl3 regulates lipid metabolism in mice","volume":"30","author":"Koishi","year":"2002","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.tcm.2023.01.008_bib0012","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1006\/geno.1999.6041","article-title":"Identification of a mammalian angiopoietin-related protein expressed specifically in liver","volume":"62","author":"Conklin","year":"1999","journal-title":"Genomics"},{"issue":"47","key":"10.1016\/j.tcm.2023.01.008_bib0013","doi-asserted-by":"crossref","first-page":"36293","DOI":"10.1074\/jbc.M110.156950","article-title":"O-glycosylation modulates proprotein convertase activation of angiopoietin-like protein 3: possible role of polypeptide GalNAc-transferase-2 in regulation of concentrations of plasma lipids","volume":"285","author":"Schjoldager","year":"2010","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.tcm.2023.01.008_bib0014","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/MOL.0b013e3283630cf0","article-title":"The angiopoietin-like protein 3: a hepatokine with expanding role in metabolism","volume":"24","author":"Arca","year":"2013","journal-title":"Curr Opin Lipidol"},{"issue":"37","key":"10.1016\/j.tcm.2023.01.008_bib0015","doi-asserted-by":"crossref","first-page":"26410","DOI":"10.1074\/jbc.M113.501304","article-title":"Furin is the primary in vivo convertase of angiopoietin-like 3 and endothelial lipase in hepatocytes","volume":"288","author":"Essalmani","year":"2013","journal-title":"J Biol Chem"},{"issue":"20","key":"10.1016\/j.tcm.2023.01.008_bib0016","doi-asserted-by":"crossref","first-page":"13735","DOI":"10.1074\/jbc.M807899200","article-title":"Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL)","volume":"284","author":"Lee","year":"2009","journal-title":"J Biol Chem"},{"issue":"43","key":"10.1016\/j.tcm.2023.01.008_bib0017","doi-asserted-by":"crossref","first-page":"41804","DOI":"10.1074\/jbc.M302861200","article-title":"Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo","volume":"278","author":"Ono","year":"2003","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.tcm.2023.01.008_bib0018","doi-asserted-by":"crossref","first-page":"16168","DOI":"10.1038\/s41598-020-73388-3","article-title":"GALNT2 regulates ANGPTL3 cleavage in cells and in vivo of mice","volume":"10","author":"Li","year":"2020","journal-title":"Sci Rep"},{"issue":"25","key":"10.1016\/j.tcm.2023.01.008_bib0019","doi-asserted-by":"crossref","first-page":"9893","DOI":"10.1073\/pnas.1203563109","article-title":"Probing isoform-specific functions of polypeptide GalNAc-transferases using zinc finger nuclease glycoengineered SimpleCells","volume":"109","author":"Schjoldager","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"37","key":"10.1016\/j.tcm.2023.01.008_bib0020","doi-asserted-by":"crossref","first-page":"33742","DOI":"10.1074\/jbc.M203215200","article-title":"ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase","volume":"277","author":"Shimizugawa","year":"2002","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.tcm.2023.01.008_bib0021","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/01.ATV.0000252827.51626.89","article-title":"Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase","volume":"27","author":"Shimamura","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.tcm.2023.01.008_bib0022","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.cmet.2007.07.009","article-title":"Hepatic proprotein convertases modulate HDL metabolism","volume":"6","author":"Jin","year":"2007","journal-title":"Cell Metab"},{"issue":"48","key":"10.1016\/j.tcm.2023.01.008_bib0023","doi-asserted-by":"crossref","first-page":"19751","DOI":"10.1073\/pnas.1217552109","article-title":"Atypical angiopoietin-like protein that regulates ANGPTL3","volume":"109","author":"Quagliarini","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.tcm.2023.01.008_bib0024","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1074\/jbc.M506519200","article-title":"The fasting-induced adipose factor\/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity","volume":"281","author":"Mandard","year":"2006","journal-title":"J Biol Chem"},{"issue":"37","key":"10.1016\/j.tcm.2023.01.008_bib0025","doi-asserted-by":"crossref","first-page":"28488","DOI":"10.1074\/jbc.M004029200","article-title":"Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene","volume":"275","author":"Kersten","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.tcm.2023.01.008_bib0026","article-title":"An updated ANGPTL3-4-8 model as a mechanism of triglyceride partitioning between fat and oxidative tissues","author":"Zhang","year":"2021","journal-title":"Prog Lipid Res"},{"issue":"6","key":"10.1016\/j.tcm.2023.01.008_bib0027","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/MOL.0000000000000789","article-title":"ANGPTL3 as therapeutic target","volume":"32","author":"Kersten","year":"2021","journal-title":"Curr Opin Lipidol"},{"issue":"1","key":"10.1016\/j.tcm.2023.01.008_bib0028","first-page":"70","article-title":"Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans","volume":"119","author":"Romeo","year":"2009","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.tcm.2023.01.008_bib0029","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/ng.291","article-title":"Common variants at 30 loci contribute to polygenic dyslipidemia","volume":"41","author":"Kathiresan","year":"2009","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.tcm.2023.01.008_bib0030","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/ng.75","article-title":"Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans","volume":"40","author":"Kathiresan","year":"2008","journal-title":"Nat Genet"},{"issue":"7307","key":"10.1016\/j.tcm.2023.01.008_bib0031","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nature09270","article-title":"Biological, clinical and population relevance of 95 loci for blood lipids","volume":"466","author":"Teslovich","year":"2010","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.tcm.2023.01.008_bib0032","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1161\/ATVBAHA.111.238766","article-title":"Prevalence of ANGPTL3 and APOB gene mutations in subjects with combined hypolipidemia","volume":"32","author":"Noto","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5\u20136","key":"10.1016\/j.tcm.2023.01.008_bib0033","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.cca.2011.11.020","article-title":"Identification of a novel mutation in the ANGPTL3 gene in two families diagnosed of familial hypobetalipoproteinemia without APOB mutation","volume":"413","author":"Martin-Campos","year":"2012","journal-title":"Clin Chim Acta"},{"issue":"1","key":"10.1016\/j.tcm.2023.01.008_bib0034","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/CIRCGENETICS.111.960674","article-title":"Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3","volume":"5","author":"Pisciotta","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"issue":"6","key":"10.1016\/j.tcm.2023.01.008_bib0035","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1194\/jlr.M300031-JLR200","article-title":"A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice","volume":"44","author":"Ando","year":"2003","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.tcm.2023.01.008_bib0036","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N Engl J Med"},{"issue":"37","key":"10.1016\/j.tcm.2023.01.008_bib0037","doi-asserted-by":"crossref","first-page":"11630","DOI":"10.1073\/pnas.1515374112","article-title":"Hepatic ANGPTL3 regulates adipose tissue energy homeostasis","volume":"112","author":"Wang","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.tcm.2023.01.008_bib0038","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1538\/expanim.55.27","article-title":"Angptl3-null mice show low plasma lipid concentrations by enhanced lipoprotein lipase activity","volume":"55","author":"Fujimoto","year":"2006","journal-title":"Exp Anim"},{"issue":"10","key":"10.1016\/j.tcm.2023.01.008_bib0039","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.molmet.2017.06.014","article-title":"ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase","volume":"6","author":"Chi","year":"2017","journal-title":"Mol Metab"},{"issue":"6","key":"10.1016\/j.tcm.2023.01.008_bib0040","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1194\/jlr.M075689","article-title":"ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance","volume":"58","author":"Haller","year":"2017","journal-title":"J Lipid Res"},{"issue":"7","key":"10.1016\/j.tcm.2023.01.008_bib0041","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1194\/jlr.M054882","article-title":"Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion","volume":"56","author":"Wang","year":"2015","journal-title":"J Lipid Res"},{"issue":"7","key":"10.1016\/j.tcm.2023.01.008_bib0042","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1194\/jlr.M054890","article-title":"ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys","volume":"56","author":"Gusarova","year":"2015","journal-title":"J Lipid Res"},{"issue":"9","key":"10.1016\/j.tcm.2023.01.008_bib0043","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","article-title":"Angiopoietin-like protein 3 (ANGPTL3) governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance","volume":"61","author":"Adam","year":"2020","journal-title":"J Lipid Res"},{"issue":"8","key":"10.1016\/j.tcm.2023.01.008_bib0044","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1161\/CIRCRESAHA.120.317128","article-title":"LDL-cholesterol reduction by ANGPTL3 inhibition in mice is dependent on endothelial lipase","volume":"127","author":"Wu","year":"2020","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.tcm.2023.01.008_bib0045","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12933-019-0860-y","article-title":"Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management","volume":"18","author":"Luo","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"10.1016\/j.tcm.2023.01.008_bib0046","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/ATVBAHA.113.301397","article-title":"Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids","volume":"33","author":"Robciuc","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"40","key":"10.1016\/j.tcm.2023.01.008_bib0047","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","article-title":"Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia","volume":"41","author":"Gaudet","year":"2020","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.tcm.2023.01.008_bib0048","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1194\/jlr.P039875","article-title":"Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis","volume":"54","author":"Minicocci","year":"2013","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.tcm.2023.01.008_bib0049","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.tcm.2023.01.008_bib0050","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.tcm.2023.01.008_bib0051","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.tcm.2023.01.008_bib0052","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in patients with refractory hypercholesterolemia","volume":"383","author":"Rosenson","year":"2020","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.tcm.2023.01.008_bib0053","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes","volume":"111","author":"Macdonald","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"10.1016\/j.tcm.2023.01.008_bib0054","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"10.1016\/j.tcm.2023.01.008_bib0055","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","volume":"367","author":"Roth","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.tcm.2023.01.008_bib0056","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.tcm.2023.01.008_bib0057","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","article-title":"Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia","volume":"140","author":"Ahmad","year":"2019","journal-title":"Circulation"},{"issue":"32","key":"10.1016\/j.tcm.2023.01.008_bib0058","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.tcm.2023.01.008_bib0059","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 inhibition in homozygous familial hypercholesterolemia","volume":"377","author":"Gaudet","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.tcm.2023.01.008_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100198","article-title":"An anti-ANGPTL3\/8 antibody decreases circulating triglycerides by binding to a LPL-inhibitory leucine zipper-like motif","volume":"63","author":"Balasubramaniam","year":"2022","journal-title":"J Lipid Res"},{"issue":"40","key":"10.1016\/j.tcm.2023.01.008_bib0061","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1093\/eurheartj\/ehaa229","article-title":"From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases","volume":"41","author":"Landmesser","year":"2020","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.tcm.2023.01.008_bib0062","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jacc.2020.05.070","article-title":"Targeting RNA with antisense oligonucleotides and small interfering RNA: JACC State-of-the-Art Review","volume":"76","author":"Katzmann","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.tcm.2023.01.008_bib0063","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","article-title":"Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70","volume":"145","author":"Bergmark","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2023.01.008_bib0064","article-title":"RNA interference targeting hepatic angiopoietin-like protein 3 results in prolonged reductions in serum triglyceride and non-HDL-cholesterol concentrations: first human results with ARO-ANG3","author":"Watts","year":"2022","journal-title":"Preprint from Research Square"},{"issue":"16","key":"10.1016\/j.tcm.2023.01.008_bib0065","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of Bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.tcm.2023.01.008_bib0066","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11883-020-00847-7","article-title":"New pharmacological approaches to target PCSK9","volume":"22","author":"Catapano","year":"2020","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.tcm.2023.01.008_bib0067","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3389\/fcvm.2018.00199","article-title":"Non-antibody approaches to proprotein convertase subtilisin kexin 9 inhibition: siRNA, antisense oligonucleotides, adnectins, vaccination, and new attempts at small-molecule inhibitors based on new discoveries","volume":"5","author":"Nishikido","year":"2018","journal-title":"Front Cardiovasc Med"},{"issue":"7","key":"10.1016\/j.tcm.2023.01.008_bib0068","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1161\/CIRCRESAHA.117.310610","article-title":"A new approach to PCSK9 therapeutics","volume":"120","author":"Wang","year":"2017","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.tcm.2023.01.008_bib0069","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.tcm.2023.01.008_bib0070","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.tcm.2023.01.008_bib0071","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1056\/NEJMcibr1906886","article-title":"Controlling CRISPR-Cas9 gene editing","volume":"381","author":"Dowdy","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.tcm.2023.01.008_bib0072","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/CIRCULATIONAHA.117.031335","article-title":"Reduced blood lipid levels with in vivo CRISPR-Cas9 base editing of ANGPTL3","volume":"137","author":"Chadwick","year":"2018","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.tcm.2023.01.008_bib0073","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1515\/BC.2008.064","article-title":"The coming of age of virus-like particle vaccines","volume":"389","author":"Jennings","year":"2008","journal-title":"Biol Chem"},{"key":"10.1016\/j.tcm.2023.01.008_bib0074","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-pharmtox-061008-103129","article-title":"Immunodrugs: therapeutic VLP-based vaccines for chronic diseases","volume":"49","author":"Jennings","year":"2009","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"40","key":"10.1016\/j.tcm.2023.01.008_bib0075","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1016\/j.vaccine.2021.08.077","article-title":"A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice","volume":"39","author":"Fowler","year":"2021","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.tcm.2023.01.008_bib0076","article-title":"Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia","volume":"2","author":"Fukami","year":"2021","journal-title":"Cell Rep Med"},{"issue":"4","key":"10.1016\/j.tcm.2023.01.008_bib0077","first-page":"251","article-title":"FDA approves first anti-ANGPTL3 antibody, for rare cardiovascular indication","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.tcm.2023.01.008_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100060","article-title":"Existing and emerging therapies for the treatment of familial hypercholesterolemia","volume":"62","author":"Rosenson","year":"2021","journal-title":"J Lipid Res"},{"issue":"16","key":"10.1016\/j.tcm.2023.01.008_bib0079","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/j.jacc.2017.06.076","article-title":"Concerns on the genetic or therapeutic antagonism of ANGPTL3","volume":"70","author":"Luo","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2023.01.008_bib0080","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijcard.2017.10.003","article-title":"Oligonucleotides targeting ANGPTL3","volume":"256","author":"Luo","year":"2018","journal-title":"Int J Cardiol"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105017382300018X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105017382300018X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T21:15:04Z","timestamp":1715030104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105017382300018X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S105017382300018X"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2023.01.008","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2023.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}